P1, N=60, Not yet recruiting, Daré Bioscience, Inc. | Trial completion date: Jun 2026 --> Apr 2028 | Trial primary completion date: Jan 2026 --> Nov 2027

P=N/A, N=300, Completed, University Hospital, Toulouse | Recruiting --> Completed | N=200 --> 300

MA significantly improves nutritional status and ameliorates cancer-related fatigue, thereby enhancing the quality of life in patients with cancer cachexia. Our findings provide robust evidence supporting the multi-dimensional benefits of MA in cachexia management, extending beyond mere weight gain to include muscle mass preservation and patient-centered symptom relief.

P1, N=20, Recruiting, Massachusetts General Hospital

P1, N=4, Terminated, Emory University | Trial completion date: Apr 2027 --> Mar 2026 | Active, not recruiting --> Terminated; Review of Drug Supply

Integrative analysis of LR crosstalk, knockdown experiments, and molecular docking reveals potential drug targets.

P2, N=88, Not yet recruiting, Nanfang Hospital, Southern Medical University

No marked discrepancies were found in the rates of miscarriage, multiple pregnancy, and ectopic pregnancy in both groups (P > 0.05). The efficacy of GnRH-a combined with Dienogest in the treatment of EMT is remarkable, which can effectively reduce the inflammatory response, sex hormone levels, and recurrence rate, and markedly improve pregnancy, which is worth promoting its use in the clinic.

Background: Oral progestogens, including megestrol acetate (MA) and medroxyprogesterone acetate (MPA), have largely been superseded by aromatase inhibitors, tamoxifen, and selective oestrogen receptor degraders (SERDs) in oestrogen receptor-positive (ER-positive) metastatic breast cancer. While prior exposure to CDK4/6 inhibitors was associated with shorter PFS, patients without liver metastases appeared to derive the greatest benefit. These findings support a role for oral progestogens in selected patients who have exhausted standard therapeutic options.

Molecular classification may serve as a predictive tool for the efficacy of fertility preservation therapy in patients with EC and AEH and was found to be particularly useful for identifying p53 mutants, which are associated with a high risk of recurrence, as well as MMRd types, which are known to lead to poor responses to progesterone treatment.

The coordinated dysregulation of these hormone-responsive and proliferation-related molecules highlights a fundamental hormonal imbalance and proliferative disruption in progesterone-resistant AEH. This study provides a molecular framework for understanding progesterone resistance and suggests potential targets, such as SOX7, for future therapeutic strategies aimed at restoring hormonal sensitivity and controlling disease progression in conservative fertility-sparing management.

In addition, we found that progesterone administration reduced the thickness of the uterine endometrium in PCOS mice. Our findings suggest that sustained high levels of progesterone during pregnancy can enhance ovarian reproductive endocrine capacity and improve endometrial function, thereby facilitating the recovery of postpartum menstrual cycles.